About Rybelsus 3 mg (Semaglutide)
Rybelsus 3 mg (Semaglutide) contains oral Semaglutide, a GLP-1 receptor agonist used for type 2 diabetes management. It is the world’s first oral GLP-1 agonist, improving glycaemic control, reducing HbA1c, and supporting weight reduction in adults with type 2 diabetes alongside diet and exercise.
Benefits of Rybelsus 3 mg (Semaglutide)
- Blood Sugar Control: Significantly reduces HbA1c and fasting plasma glucose.
- Weight Reduction: Promotes meaningful weight loss as a secondary benefit.
- Oral Convenience: First oral GLP-1 agonist, eliminating need for injections.
How Rybelsus 3 mg (Semaglutide) Works
Semaglutide activates GLP-1 receptors in the pancreas, stimulating glucose-dependent insulin secretion and suppressing glucagon release. It also slows gastric emptying, reducing postprandial glucose spikes. Central GLP-1 receptor activation contributes to appetite suppression and weight loss.
Dosage & Usage
- Dosage: As prescribed; taken orally on an empty stomach with a small amount of water, at least 30 minutes before the first meal.
- Precautions: Not for use in type 1 diabetes or diabetic ketoacidosis; monitor for pancreatitis.
Side Effects
- Nausea or vomiting (especially early in treatment)
- Diarrhoea or constipation
- Decreased appetite
Consult your doctor before use.





Write a review